blincyto
amgen europe b.v. - blinatumomabas - prekursorių ląstelių limfoblastinė leukemija-limfoma - antinavikiniai vaistai - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
irbesartan bms
bristol-myers squibb pharma eeig - irbesartanas - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - esminės hipertenzijos gydymas. gydymas inkstų liga pacientams, sergantiems hipertenzija ir 2 tipo cukriniu diabetu dalis antihypertensive vaisto režimas (žr. skyrių 5.
absenor
orion corporation, orion pharma - natrio valproatas - pailginto atpalaidavimo tabletės - 500 mg - valproic acid
convulex retard
g.l. pharma gmbh - natrio valproatas - pailginto atpalaidavimo tabletės - 300 mg; 500 mg - valproic acid
isoptin retard
viatris sia - verapamilio hidrochloridas - pailginto atpalaidavimo tabletės - 120 mg; 240 mg - verapamil
rubis pasta
lodi sas, parc d‘activites des quatre routes, f-35390 grand fougeray (prancūzija). - difenakumas - veikliosios medžiagos cas nr.: 56073-07-5, eb nr.: 259-978-4, veikliosios medžiagos pavadinimas: difenakumas, koncentracija: 0.005% , veiklioji - rodenticidai
lenalidomide grindeks
as grindeks - lenalidomidas - kietosios kapsulės - 25 mg - lenalidomide
polalid
zakłady farmaceutyczne polpharma s.a. - lenalidomidas - kietosios kapsulės - 7,5 mg - lenalidomide
polalid
zakłady farmaceutyczne polpharma s.a. - lenalidomidas - kietosios kapsulės - 10 mg - lenalidomide
polalid
zakłady farmaceutyczne polpharma s.a. - lenalidomidas - kietosios kapsulės - 15 mg - lenalidomide